Myriad Readying to Take BRACAnalysis into Pivotal Trial for AstraZeneca's Olaparib as Companion Dx | GenomeWeb

This story has been updated to add information from Jonathan Ledermann's presentation at the ASCO annual meeting. Originally published June 1.

CHICAGO -- Myriad Genetics has submitted its first investigational device exemption application with the US Food and Drug Administration for BRACAnalysis, laying the regulatory groundwork for the test to be studied in five pivotal trials to pick out best responders to AstraZeneca's PARP inhibitor olaparib.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.